Extended Data Fig. 2: Response and survival for sequenced vs. non-sequenced patients in each cohort. | Nature Medicine

Extended Data Fig. 2: Response and survival for sequenced vs. non-sequenced patients in each cohort.

From: Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma

Extended Data Fig. 2: Response and survival for sequenced vs. non-sequenced patients in each cohort.

Comparison of PFS (a,c,e) and OS (b,d,f) included and excluded patients for (a-b) WES, (c-d) RNA-seq, and (e-f) immunofluorescence analysis. Left panels, CM-010; middle panels, CM-025 patients treated with PD-1 blockade; right panels, CM-025 patients treated with mTOR inhibition. CM-025 patients treated with PD-1 blockade who were included in WES analysis had shorter OS than patients not included (p < 0.05). There were no other significant differences between included and excluded patients (two-sided log-rank test). g, There were no significant differences in PFS or OS among anti-PD-1 treated patients in the three trial cohorts.

Back to article page